charmhealth names Gary Lakin as new CEO

Australia’s leading developer and supplier of specialist oncology electronic medical record and clinical information systems, charmhealth, today announced the appointment of Gary Lakin as Chief Executive Officer.

With a health IT career spanning over three decades – half of that in Australia – Mr Lakin brings extensive experience in healthcare enterprise software and technology having worked with a broad range of organisations; from start-ups to large corporate entities across the North American and Australasian regions.

Anne-Marie Birkill, charmhealth Chair, commented: “This is a key appointment at an important time for charmhealth and we are certain that Gary’s leadership qualities combined with his strategic thinking and deep health sector experience make him the right person to drive the company to success over the coming years.”

“I am confident that Gary’s approach and his track record of delivering results in health IT businesses will deliver value to shareholders and clients alike.”

Prior to joining charmhealth, Mr Lakin was Vice President of Alcidion Corporation where he drove the transformation of the organisation into a more market-driven, commercially successful health informatics company. He has also held senior management, consulting, sales and marketing roles with companies such as Cerner, Ascribe, Microsoft and HIMSS Analytics.

“I have long admired charmhealth for its commitment to quality and its spirit of innovation,” said Mr. Lakin. “My work has always been motivated by a passion for using technology to address the pressing problems facing healthcare, so I’m deeply honoured to join such a dynamic organisation that is equally committed to developing and delivering high-impact solutions for today’s healthcare organisations.”

Mr Lakin also commented: “Given the company’s strong position in the marketplace, I believe there are extraordinary opportunities to grow and build value. I look forward to working closely with charmhealth employees, clients, shareholders and partners to deliver new and innovative solutions that assist healthcare professionals provide quality care for the chronically ill throughout their patient journey.”

charmhealth is a portfolio company of the OneVentures Innovation Fund.

For more information, contact:

Karin Chiu
Honner Media
Tel: +61 2 8248 3744

Anne-Marie Birkill
OneVentures General Partner and charmhealth Chair of the Board
Mobile: +61 (0) 419 789 401
Email :

About charmhealth:

charmhealth develops, delivers and supports state-of-the-art software solutions to manage the many functions of Oncology Facilities in private and public hospital settings.

To date over 40 such facilities, supporting more than 45,000 patients annually, are licensed to use Charm software, including the Peter Macallum Cancer Centre, Queensland Health, ACT Health and Cabrini Health.

charmhealth is currently developing its next generation product, CharmNG. CharmNG expands the extensive functional capabilities of its current generation CHARM product and provides a range of deployment options from traditional on premise to a fully hosted offering. CharmNG provides an advanced platform for charmhealth to move beyond the oncology market to service other chronic care sectors.

charmhealth solutions mitigate compliance, clinical, financial and administrative risk by ensuring the most up to date patient information is available to all healthcare providers, in real time, when making important clinical and prescribing decisions.

Read more about charmhealth at

About OneVentures:

OneVentures is a venture capital firm that invests in emerging Australian technology companies with true breakout potential, differentiated technology and compelling business models in the clean technology, information technology and life sciences sectors.

OneVentures is managed by a team of partners with a skills set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.

The OneVentures Innovation Fund is a $40 million venture capital fund formed as an Early Stage Venture Capital Limited Partnership. OneVentures is supported by the Australian Government through the IIF program with this funding matched by institutional investors, individual high net worth investors and family offices. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.

Read more about OneVentures at

Posted in — Media Release

You may also like

29 May 2020

Vaxxas announces that MSD exercises option to apply novel immune system activation platform for vaccine candidate

11 April 2013

OneVentures team ‘charmed’ by Queensland Health-IT company

10 March 2016

Thinking beyond the ideas boom: What Australia really needs is later stage capital and experience

30 April 2020

Clinical Genomics expands strategic relationship with Quest Diagnostics and further increases momentum for innovative first-line colorectal cancer screening blood test

02 June 2021

Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine

16 September 2018

VC-backed women’s health company Madorra to begin clinical trials in Australia

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor